EMBC (Embecta) Long-Term Debt: $1,317 Mil (As of Mar. 2026)


EMBC Embecta Corp EMBC
53 GF Score
Price $3.35
GF Value $12.68
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Embecta Long-Term Debt?

Embecta EMBC -0.45% 53 Long-Term Debt is $1,317 Mil as of Mar. 2026. GuruFocus rates EMBC with a GF Score™ of 53/100 and a GF Value™ of $12.68 (Possible Value Trap). The stock has 6 warning signs investors should review.

Embecta's Long-Term Debt for the quarter that ended in Mar. 2026 was $1,317 Mil.

Embecta's quarterly Long-Term Debt declined from Sep. 2025 ($1,389 Mil) to Dec. 2025 ($1,353 Mil) and declined from Dec. 2025 ($1,353 Mil) to Mar. 2026 ($1,317 Mil).

Embecta's annual Long-Term Debt declined from Sep. 2023 ($1,594 Mil) to Sep. 2024 ($1,565 Mil) and declined from Sep. 2024 ($1,565 Mil) to Sep. 2025 ($1,389 Mil).

Embecta  (NAS:EMBC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Embecta Long-Term Debt Related Terms

Embecta Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Embecta's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embecta Long-Term Debt Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Long-Term Debt
Get a 7-Day Free Trial 0.00 1,598.10 1,593.90 1,565.30 1,388.70

Embecta Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,509.10 1,458.80 1,388.70 1,352.90 1,316.90
EMBC
53GF Score
Embecta Corp EMBC
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $1,317 Mil mean?
Embecta (EMBC) has a Long-Term Debt of $1,317 Mil as of Mar. 2026.
Is Embecta's Long-Term Debt too high?
Embecta's current Long-Term Debt is $1,317 Mil. Overall, Embecta has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Embecta's Long-Term Debt compare to KRMD and SMTI?
Embecta's Long-Term Debt of $1,317 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Embecta's current Long-Term Debt is $1,317 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embecta stock overvalued right now?
Based on GuruFocus' analysis, Embecta (EMBC) is currently considered Possible Value Trap. The stock's GF Value™ is $12.68, compared to a current price of $3.35 — trading 73.6% below its estimated fair value. The current Long-Term Debt is $1,317 Mil. Embecta's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Embecta (EMBC), the current Long-Term Debt is $1,317 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embecta (EMBC) Overvalued in 2026?

Based on GuruFocus' analysis, Embecta stock appears to be undervalued. The current stock price of $3.35 is trading 73.6% below its estimated GF Value™ of $12.68. GuruFocus considers Embecta to be Possible Value Trap.

Key valuation signals for EMBC:

  • Long-Term Debt: $1,317 Mil
  • GF Value™: $12.68 vs. price of $3.35 (73.6% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embecta Business Description

Other Exchanges JX7:Germany
Address 300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
53GF Score

Get the complete analysis for EMBC

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.35
Price
$12.68
GF Value